Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Nov 16;11(11):CD005474.
doi: 10.1002/14651858.CD005474.pub2.

Zuclopenthixol dihydrochloride for schizophrenia

Edward J Bryan  1 , Marie Ann Purcell, Ajit Kumar
Affiliations
Meta-Analysis

Zuclopenthixol dihydrochloride for schizophrenia

Edward J Bryan et al. Cochrane Database Syst Rev. .

Abstract

Background: Oral zuclopenthixol dihydrochloride (Clopixol) is an anti-psychotic treatment for people with psychotic symptoms, especially those with schizophrenia. It is associated with neuroleptic malignant syndrome, a prolongation of the QTc interval, extra-pyramidal reactions, venous thromboembolism and may modify insulin and glucose responses.

Objectives: To determine the effects of zuclopenthixol dihydrochloride for treatment of schizophrenia.

Search methods: We searched the Cochrane Schizophrenia Group's Trials Register (latest search 09 June 2015). There were no language, date, document type, or publication status limitations for inclusion of records in the register.

Selection criteria: All randomised controlled trials (RCTs) focusing on zuclopenthixol dihydrochloride for schizophrenia. We included trials meeting our inclusion criteria and reporting useable data.

Data collection and analysis: We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention-to-treat basis. For continuous data, we estimated the mean difference (MD) between groups and its 95% CI. We employed a random-effect model for analyses. We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE.

Main results: We included 20 trials, randomising 1850 participants. Data were reported for 12 comparisons, predominantly for the short term (up to 12 weeks) and inpatient populations. Overall risk of bias for included studies was low to unclear.Data were unavailable for many of our pre-stated outcomes of interest. No data were available, across all comparisons, for death, duration of stay in hospital and general functioning.Zuclopenthixol dihydrochloride versus: 1. placeboMovement disorders (EPSEs) were similar between groups (1 RCT, n = 28, RR 6.07 95% CI 0.86 to 43.04 very low-quality evidence). There was no clear difference in numbers leaving the study early (2 RCTs, n = 100, RR 0.29, 95% CI 0.01 to 6.60, very low-quality evidence). 2. chlorpromazineNo clear differences were found for the outcomes of global state (average CGI-SI endpoint score) (1 RCT, n = 60, MD 0.00, 95% CI -0.49 to 0.49) or movement disorders (EPSEs) (3 RCTs, n = 199, RR 0.94, 95% CI 0.61 to 1.45), both very low-quality evidence. More people left the study early for any reason from the zuclopenthixol group (6 RCTs, n = 766, RR 0.54, 95% CI 0.36 to 0.81, low-quality evidence). 3. chlorprothixeneThere was no clear difference in numbers leaving the study early for any reason (1 RCT, n = 20, RR 1.00, 95% CI 0.34 to 2.93, very low-quality evidence). 4. clozapineNo useable data were presented. 5. haloperidolNo clear differences between treatment groups were found for the outcomes global state score (average CGI endpoint score) (1 RCT, n = 49, MD 0.13, 95% CI -0.30 to 0.55) or leaving the study early (2 RCTs, n = 141, RR 0.99, 95% CI 0.72 to 1.35), both very low-quality evidence. 6. perphenazineThose receiving zuclopenthixol were more likely to require medication in the short term for EPSEs than perphenazine (1 RCT, n = 50, RR 1.90, 95% CI 1.12 to 3.22, very low-quality evidence). Similar numbers left the study early (2 RCTs, n = 104, RR 0.63, 95% CI 0.27 to 1.47, very low-quality evidence). 7. risperidoneThose receiving zuclopenthixol were more likely to require medications for EPSEs than risperidone (1 RCT, n = 98,RR 1.92, 95% CI 1.12 to 3.28, very low quality evidence). There was no clear difference in numbers leaving the study early ( 3 RCTs, n = 154, RR 1.30, 95% CI 0.84 to 2.02) or in mental state (average PANSS total endpoint score) (1 RCT, n = 25, MD -3.20, 95% CI -7.71 to 1.31), both very low-quality evidence). 8. sulpirideNo clear differences were found for global state (average CGI endpoint score) ( 1 RCT, n = 61, RR 1.18, 95% CI 0.49 to 2.85, very low-quality evidence), requiring hypnotics/sedatives (1 RCT, n = 61, RR 0.60, 95% CI 0.27 to 1.32, very low-quality evidence) or leaving the study early (1 RCT, n = 61, RR 2.07 95% CI 0.97 to 4.40, very low-quality evidence). 9. thiothixeneNo clear differences were found for the outcomes of 'global state (average CGI endpoint score) (1 RCT, n = 20, RR 0.50, 95% CI 0.17 to 1.46) or leaving the study early (1 RCT, n = 20, RR 0.57, 95% CI 0.24 to 1.35), both very low-quality evidence). 10. trifluoperazineNo useable data were presented. 11. zuclopenthixol depotThere was no clear difference in numbers leaving the study early (1 RCT, n = 46, RR 1.95, 95% CI 0.36 to 10.58, very low-quality evidence). 12. Zuclopenthixol dihydrochloride (cis z isomer) versus zuclopenthixol (cis z/trans e isomer)There were no clear differences in reported side-effects ( 1 RCT, n = 57, RR 1.34, 95% CI 0.82 to 2.18, very low-quality evidence) and in numbers leaving the study early (4 RCTs, n = 140, RR 2.15, 95% CI 0.49 to 9.41, very low-quality evidence).

Authors' conclusions: Zuclopenthixol dihydrochloride appears to cause more EPSEs than clozapine, risperidone or perphenazine, but there was no difference in EPSEs when compared to placebo or chlorpromazine. Similar numbers required hypnotics/sedatives when zuclopenthixol dihydrochloride was compared to sulpiride, and similar numbers of reported side-effects were found when its isomers were compared. The other comparisons did not report adverse-effect data.Reported data indicate zuclopenthixol dihydrochloride demonstrates no difference in mental or global states compared to placebo, chlorpromazine, chlorprothixene, clozapine, haloperidol, perphenazine, sulpiride, thiothixene, trifluoperazine, depot and isomers. Zuclopenthixol dihydrochloride, when compared with risperidone, is favoured when assessed using the PANSS in the short term, but not in the medium term.The data extracted from the included studies are mostly equivocal, and very low to low quality, making it difficult to draw firm conclusions. Prescribing practice is unlikely to change based on this meta-analysis. Recommending any particular course of action about side-effect medication other than monitoring, using rating scales and clinical assessment, and prescriptions on a case-by-case basis, is also not possible.There is a need for further studies covering this topic with more antipsychotic comparisons for currently relevant outcomes.

PubMed Disclaimer

Conflict of interest statement

Edward Bryan: none known.

Marie Purcell: none known.

Ajit Kumar: none known.

Figures

1
1
Study flow diagram ‐ update 2016.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Aaes‐Jorgensen 1981 {published data only}
    1. Aaes‐Jorgensen T, Gravem A, Jorgensen A. Serum levels of the isomers of clopenthixol in patients given cis(Z)‐clopenthixol or cis(Z)‐trans(E)‐clopenthixol. Acta Psychiatrica Scandinavica Supplementum 1981;294:70‐7. [MEDLINE: ; PMID 6951396] - PubMed
Arango 2006 {published data only}
    1. Arango C, Bombin I, Gonzalez‐Salvador T, Garcia‐Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. European Psychiatry 2006;21(1):34‐40. [MEDLINE: ] - PubMed
    1. Bombin I, Arango C. Antipsychotic treatment adherence and violence in schizophrenia outpatients: a randomized prospective trial. European Neuropsychopharmacology 2004;14(Suppl 3):S289.
Balasubramanian 1991 {published data only}
    1. Balasubramanian K, Baloch N, Briscoe MH, Chattree S, Cooper CJ, Durani SK, et al. A double blind multicentre comparison of oral zuclopenthixol and oral chlorpromazine in the treatment of acute psychosis. British Journal of Clinical Research 1991;n/a:149‐56. [MEDLINE: ; PMID 5600894] - PubMed
Ban 1975 {published data only}
    1. Ban TA, Lehmann HE, Sterlin C, Climan M. Comprehensive clinical studies with thiothixene. Diseases of the Nervous System 1975;36(9):473‐7. [MEDLINE: ; PMID 240651] - PubMed
    1. Lehmann HE, Ban TA. Thiothixene versus chlorprothixene versus clopenthixol. Psychopharmacology Bulletin 1970;6(4):118‐20. [13027]
    1. Sterlin C, Ban TA, Jarrold L. The place of thiothixene among the thioxanthenes. Current Therapeutic Research Clinical and Experimental 1972;14(4):205‐14. [MEDLINE: ; PMID 4623599] - PubMed
CSzG Study ID 9828 2005 {published data only}
    1. 刘启珍, 王慧芳, 陈洪来, 刘翠珍. [Title only available in Chinese characters] [氯噻吨与氯丙嗪治疗精神分裂症的对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2005;18(3):175‐6.
Dehnel 1968 {published data only}
    1. Dehnel LL, Vestre ND, Schiele BC. A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population. Current Therapeutic Research Clinical and Experimental 1968;10:169‐76. [MEDLINE: ; PMID 4967871] - PubMed
Fagerlund 2004 {published data only}
    1. Fagerlund B, Mackeprang T, Gade A, Hemmingsen R, Glenthoj BY. Effects of low‐dose risperidone and low‐dose zuclopenthixol on cognitive functions in fisrt‐episode drug‐naive schizophrenic patients. CNS Spectrums. United States of America, 2004; Vol. 9, issue 5:364‐74. [MEDLINE: ] - PubMed
Fischer‐Cornelssen 1976 {published data only}
    1. Fischer‐Cornelssen KA, Ferner UJ. An example of European multicentre trials: multispectral analysis of clozapine. Psychopharmacology Bulletin 1976;12:34‐9. - PubMed
Glenthoj 2007 {published data only}
    1. Glenthoj A, Glenthoj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, Jernigan TL, et al. Basal ganglia volumes in drug‐naive first‐episode schizophrenia patients before and after short‐term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Research 2007;154(3):199‐208. [MEDLINE: ] - PubMed
    1. Glenthoj B, Fagerlund B, Rasmussen H, Pinborg L, Svarer C, Friberg L, et al. Extrastriatal dopamine D2/D3‐receptors in drug‐naïve first‐episode schizophrenic patients: relation to psychopathology, cognition and treatment outcome. International Journal of Neuropsychopharmacology 2008;11(Suppl 1):6‐7.
    1. Glenthoj B, Glenthoj A, Jagersma E, Pagsberg AK, Hemmingsen RP, Svarer C, et al. Effects of typical and atypical antipsychotic medication on caudate nucleus volume in first‐episode schizophrenic patients: relation to dopamine d2/3 receptor occupancy psychopathology and extrapyramidal side‐effects. Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005.
Gravem 1978 {published data only}
    1. Gravem A, Engstrand E, Guleng RJ. Cis(Z)‐clopenthixol and clopenthixol (Sordinol) in chronic psychotic patients. A double‐blind clinical investigation. Acta Psychiatrica Scandinavica 1978;58(5):384‐8. [MEDLINE: ; PMID 362830] - PubMed
Gravem 1981 {published data only}
    1. Gravem A, Bugge A. Cis(Z)‐clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. A double‐blind clinical investigation. Acta Psychiatrica Scandinavica Supplementum 1981;294:13‐24. [MEDLINE: ; PMID 7041515] - PubMed
Heikkila 1981 {published data only}
    1. Heikkila L, Karsten D, Valli K. A double‐blind clinical investigation of cis(Z)‐clopenthixol and clopenthixol in chronic schizophrenic patients. Acta Psychiatrica Scandinavica Supplementum 1981;294:25‐9. [MEDLINE: ; PMID 7041516] - PubMed
Heikkila 1981a {published data only}
    1. Heikkila L, Eliander H, Vartiainen H, Turunen M, Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double‐blind, multicentre study. Current Medical Research and Opinion 1992;12(9):594‐603. [EMBASE 1992128093] - PubMed
    1. Heikkila L, Laitinen J, Vartiainen H. Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation. Acta Psychiatrica Scandinavica Supplementum 1981;294:30‐8. [MEDLINE: ; PMID 7041517] - PubMed
Huttunen1995 {published data only}
    1. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel‐group trial. Acta Psychiatrica Scandinavica 1995;91(4):271‐7. - PubMed
    1. Huttunen MO, Piepponen T. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes. European Psychiatry 1994;9(Suppl 1):85. - PubMed
    1. Moller HJ, Huttunen MO. The prevalence of extrapyramidal symptoms during short and long term treatment with risperidone. 7th Biennial European Winter Workshop on Schizophrenia; 1994 Jan 23‐28; Les Diablerets, Switzerland 1994;11(2):106. [MEDLINE: ; PMID 8104468] - PubMed
Kingstone 1970 {published data only}
    1. Kingstone E, Kolivakis T, Kossatz I. Double blind study of clopenthixol and chlorpromazine in acute hospitalized schizophrenics. Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie 1970;3(1):41‐5. [MEDLINE: ; PMID 4909377] - PubMed
Kordas 1968 {published data only}
    1. Kordas SK, Kazamias NG, Georgas JG, Papadokostakis JG. Clopenthixol: a controlled trial in chronic hospitalized schizophrenic patients. British Journal of Psychiatry 1968;114(512):833‐6. [MEDLINE: ; PMID 4874163] - PubMed
Mahadevan 1991 {published data only}
    1. Mahadevan K, Gadhvi HM, Suri AK, Hussain MF, Sharma VK, Sharma SK, et al. A multicentre comparison of oral zuclopenthixol dihydrochloride and oral sulpiride in the treatment of acute schizophrenia. British Journal of Clinical Research 1991;2:13‐20. [Cochrane Library CN‐00282616]
Remvig 1987 {published data only}
    1. Remvig J, Larsen H, Rask P, Skausig OB, Skov S, Stromgren LS. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double‐blind multicentre study. Pharmacopsychiatry 1987;20(4):147‐54. [MEDLINE: ; PMID 3615572] - PubMed
Serafetinides 1972 {published data only}
    1. Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8(4):214‐6. [MEDLINE: ; PsycINFO 52‐05954; PMID 4589640] - PubMed
    1. Serafetinides EA. Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System 1973;34(3):190‐1. [MEDLINE: ; PsycINFO 1973‐29665‐001; PMID 4715636] - PubMed
    1. Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7(3):263‐7. [MEDLINE: ; PsycINFO 52‐03694; PMID 4586833] - PubMed
    1. Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease 1972;154(1):31‐42. [MEDLINE: ; PMID 4550211] - PubMed
    1. Serafetinides EA, Willis D. A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry 1973;8(4):245‐7. - PubMed
Wang 1995a {published data only}
    1. Wang R. Double blind study of clopenthixsol treating schizophrenia. Medical Journal of Chinese Civil Administration 1995; Vol. 7, issue 1:4‐5, 7.

References to studies excluded from this review

Aaes‐Jorgensen 1981a {published data only}
    1. Aaes‐Jorgensen T. Serum concentrations of cis(Z)‐ and trans(E)‐clopenthixol after administration of cis(Z)‐clopenthixol and clopenthixol to human volunteers. Acta Psychiatrica Scandinavica Supplementum 1981;294:64‐9. [MEDLINE: ; PMID 6951395] - PubMed
Ahlfors 1980 {published data only}
    1. Ahlfors UG, Dencker SJ, Gravem A, Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double‐blind Nordic multicentre trial. Acta Psychiatrica Scandinavica Supplementum 1980;279:77‐91. [MEDLINE: ; PMID 6996426] - PubMed
Al Haddad 1996 {published data only}
    1. Al Haddad MK, Kamel C, Mawgood MA, Sequeria RP. Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses,affective psychoses and paranoid states: a controlled clinical trial. Arab Journal of Psychiatry 1996;7(1):44‐54. [PsycINFO 2001‐16512‐004]
Arango 2002 {published data only}
    1. Arango C, Bombýn I, Bobes´J, Gonzalez‐, Cabeza Garcýa‐, Salvador MT. Prediction and prevention of violence in schizophrenia outpatients: preliminary report. Schizophrenia Research 2002;53(3 Suppl.1):233. [MEDLINE: ]
Baastrup 1993 {published data only}
    1. Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica 1993;37(1):48‐58. [MEDLINE: ; PMID 8093824] - PubMed
Bereen 1987 {published data only}
    1. Bereen FJ, Harte FB, Maguire J, Singh AN. The use of oral zuclopenthixol in the treatment of functional psychotic illness. Pharmatherapeutica 1987;5(1):61‐8. - PubMed
Bhattacharya 1987 {published data only}
    1. Bhattacharya SN, Ghoshal J, Sharma SK, Halstead N, John B, Launer MA, et al. Acute functional psychoses:treatment with zuclopenthixol dihydrochloride ('Clopixol') tablets. Pharmatherapeutica 1987;5(1):1‐8. - PubMed
Bobon 1989 {published data only}
    1. Bobon D, Bleeker E. Zuclopenthixol acetate and haloperidol in acute psychotic patients ‐ a randomized multicentre study. 2nd Congress of the European College of Neuropsychopharmacology; 1989 May 24‐26; Gothenburg, Germany. 1989. [MEDLINE: ; PMID 240651] - PubMed
    1. Bobon D, Bleeker E. Zuclopenthixol acetate and haloperidol in acute psychotic patients ‐ a randomized multicentre study. New Strategies in the Treatment of Aggressive, Acutely Psychotic Patients. Proceedings of the 8th World Congress of Psychiatry; 1989 October 13‐19, Athens, Greece. Excerpta Medica, 1989:47‐59. [MEDLINE: ; PMID 240651] - PubMed
Bourdouxhe 1987 {published data only}
    1. Bourdouxhe S, Mirel J, Denys W, Bobon D. Zuclopenthixol acetate and haloperidol in acute psychoses ‐ results of the AMDP subgroup of a Belgian multicenter study [L'acetate de zuclopenthixol et l'haloperidol dans la psychose aigue ‐ Resultats du sous groupe AMDP d'une etude multicentrique belge]. Acta Psychiatrica Belgica 1987;87(2):236‐44. [MEDLINE: ; PsycINFO 26‐73137; PMID 3618274] - PubMed
Brook 1998 {published data only}
    1. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. 1997. [MEDLINE: ; PMID 7542829] - PubMed
    1. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Unpublished Report submitted to Human Psychopharmacology Clinical and Experimental 1996. [MEDLINE: ; PMID 7542829] - PubMed
    1. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Human Psychopharmacology 1998;13(1):17‐20. [EMBASE 1998035700]
Burke 2002 {published data only}
    1. Burke JG, Reveley MA. Improved antisaccade performance with risperidone in schizophrenia. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72:449‐54. - PMC - PubMed
Chin 1998 {published data only}
    1. Chin CN, Hamid AR, Philip G, Ramlee T, Mahmud M, Zulkifli G, et al. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Medical Journal of Malaysia 1998;53(4):365‐71. [MEDLINE: ; PsycINFO 52‐05954; PMID 4589640] - PubMed
Chouinard 1991 {published data only}
    1. Chouinard G, Safadi G, Beauclair L. A double‐blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Journal of Clinical Psychopharmacology 1994;14(6):377‐84. [MEDLINE: ; PMID 7884017] - PubMed
    1. Chouinard G, Safadi G, Beauclair L. The management of acutely schizophrenic patients newly admitted from the emergency room: a double‐blind clinical trial comparing zuclopenthixol acetate and liquid haloperidol. Modern Trends in the Treatment of Chronic Schizophrenia. Proceedings of a Symposium; 1991 June 10, Florence, Italy. Excerpta Medica, 1991:35‐43. [MEDLINE: ; PMID 7884017] - PubMed
Clark 1969 {published data only}
    1. Clark. Sordinol versus chlorpromazine versus placebo. Psychopharmacology Bulletin 1969;3:54‐6. [01003]
CTRI‐2014‐07‐004712 {published data only}
    1. CTRI‐2014‐07‐004712. Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine. Http://apps.who.int/trialsearch/Trial.aspx?TrialID=CTRI/2014/07/004712 2014.
    1. Mythri SV, Tharyan P, Sunder S, Kattula D, Kirubakaran R, Adams CE. Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine [A comparative study of the effects of an intramuscular injection of zuclopenthixol acetate versus an intramuscular injection of a combination of haloperidol plus promethazine in people with violence or agitation presenting to a psychiatric hospital as an emergency]. Study Protocol 2013.
Den 2000 {published data only}
    1. Boer JA, Vahlne JO, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179‐89. [EMBASE 2000170004] - PubMed
Dencker 1980 {published data only}
    1. Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double‐blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatrica Scandinavica Supplementum 1980;279:10‐28. [MEDLINE: ; PMID 6931470] - PubMed
    1. Dencker SJ, Malm U, Jorgensen A, Overo KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome. Acta Psychiatrica Scandinavica Supplementum 1980;279:55‐63. [MEDLINE: ; PMID 6931473] - PubMed
Dom 1978 {published data only}
    1. Dom R, Mesmaecker L, Broucke M, Hest T, Baro F. Maintenance treatment of chronic schizophrenic patients. A study with the long‐acting thioxanthene derivative, cis(Z)‐clopenthixol decanoate‐sordinol depot. Acta Psychiatrica Scandinavica 1978;57(4):299‐304. [MEDLINE: ; PMID 352094] - PubMed
Fagerlund 2003 {published data only}
    1. Fagerlund B, Mackeprang T, Gade A, Glenthoj BY. Effects of risperidone and zuclopenthixol on cognitive deficits in drug‐naive first episode schizophrenic patients. Schizophrenia Research 2003;60:133‐4. [CN‐00394142]
Fan 1999 {published data only}
    1. Fan S, Sun ZG, Li J. The comparison of effects of clopenthixal and clozapine in the treatment of schizophrenia [氯噻噸與氯氮平治療精神分裂癥的效果比較]. Acta Acadimae Medicinae Qingdao 1999; Vol. 35, issue 2:125‐7.
Fensbo 1990 {published data only}
    1. Fensbo C. Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients ‐ A controlled multicenter study. Meeting of the Scandinavian Society for Psychopharmacology (1989, Copenhagen, Denmark) [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift 1990;44(3):295‐7. [PsycINFO 28‐73892]
Fricchione 2010 {published data only}
    1. Fricchione Parise V, Balletta G, Manna G. Risperidone depot versus zuclopenthixol depot for schizophrenia and schizophrenialike psychoses: Real world outcomes. European Neuropsychopharmacology 2010; Vol. 1:472‐3.
Galdersi 1994 {published data only}
    1. Galderisi S, Maj M, Mucci A, Bucci P, Kemali D. QEEG alpha1 changes after a single dose of high‐potency neuroleptics as a predictor of short‐term response to treatment in schizophrenic patients. Biological Psychiatry 1994;35(6):367‐74. [MEDLINE: ; EMBASE 1994114037; PMID 8018782] - PubMed
Glenthoj 2000 {published data only}
    1. Glenthoj BY, Mackeprang T, Fagerlund B, Hemmingsen R. Effects of antipsychotics on information‐processing and extrastriatal dopamine d2/d3 receptors in first‐episode drug‐naive schizophrenic patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10‐14; San Juan; Puerto Rico. 2000:191. [MEDLINE: ; PMID 7756183] - PubMed
    1. Glenth¢j BY, Mackeprang T, Fagerlund B, Hemmingsen RP. Effects of antipsychotic treatment on prepulse inhibition of the startle response (ppi) and cognition in first episode drug‐naive schizophrenic patients. Schizophrenia Research 2001;49(1,2):133. [PsycINFO 2001‐16512‐004]
Gravem 1990 {published data only}
    1. Gravem A, Elgen K. Cis(Z) clopenthixol. The neuroleptically active isomer of clopenthixol. A presentation of five double blind clinical investigations and other studies with cis(Z) clopenthixol (Cisordinol(R), Clopixol(R)). Acta Psychiatrica Scandinavica, Supplementum 1981;64(294):5‐12. [MEDLINE: ; PMID 6122337] - PubMed
    1. Gravem Arne, Tove AJ. Co‐injection of zuclopenthixol acetate and zuclopenthixol decanoate. Nordisk Psykiatrisk Tidsskrift 1990;44(4):403‐5. [PsycINFO 78‐07960]
Hicklin 1967 {published data only}
    1. Hicklin A, Angst J. Retrospective and prospective studies on the clinical effect of clopenthixol (sordinol) in endogenous phychoses [Retrospektive und prospektive Studie uber die klinische Wirkung von Clopenthixol (Sordinol) bei endogenen Psychosen]. Schweizerische Medizinische Wochenschrift. Journal Suisse De Medecine 1967;97(19):615‐21. [MEDLINE: ; PMID 5600894] - PubMed
Hovens 2003 {published data only}
    1. Hovens JEJM, Beijeman S, Tollenar J, Dries PJT, Loonen AJM. Risperidone versus zuclopenthixol in acute psychosis in emergency psychiatry: a prospective naturalistic study. Journal of the European College of Neuropsychopharmacology 2003;13(4):S293.
Hovens 2005 {published data only}
    1. Hovens JE, Dries PJT, Melman CTM, Wapenaar RJC, Loonen AJM. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open‐label study. Journal of Psychopharmacology 2005; Vol. 19, issue 1:51‐7. [MEDLINE: ] - PubMed
Huang 2001 {published data only}
    1. Huang SH, Pan YH, Wu FY, Qiu YP. Comparison of clopenthixol decanoate to chlorpromazine in the treatment of schizophrenia. Chinese General Practice 2001;4(10):775‐6. [CN‐00393723]
Karsten 1981 {published data only}
    1. Karsten D, Kivimaki T, Linna SL, Pollari L, Turunen S. Neuroleptic treatment of oligophrenic patients. A double‐blind clinical multicentre trial of cis(Z)‐clopenthixol and haloperidol. Acta Psychiatrica Scandinavica Supplementum 1981;294(64):39‐45. [MEDLINE: ; PMID 7041518] - PubMed
Knegtering 2002a {published data only}
    1. Knegtering H, Castelein S, Linde J, Bous J. Sexual dysfunctions and serum prolactin levels in patients using risperidone or quetiapine: a randomised trial. Schizophrenia Research 2002;53(3 Suppl 1):163.
Koskinen 1991 {published data only}
    1. Koskinen T, Wistedt B, Thelander S. Zuclopenthixol decanoate vs haloperidol decanoate: a double‐blind comparative trial. 5th World Congress of Biological Psychiatry; 1991 Jun 9‐14; Florence, Italy. 1991:563‐5. [MEDLINE: ; PMID 7756183] - PubMed
Kristiansen 2001 {published data only}
    1. Kristiansen KT, Mackeprang T, Fink‐Jensen A, Hemmingsen RP, Glenth¢j BY. Effects of antipsychotics and other agents on prepulse inhibition of the starlte response(ppi). Schizophrenia Research 2001;49(1,2):216. [PsycINFO 2001‐16512‐004]
Kristiansen 2003 {published data only}
    1. Kristiansen KT, Mackeprang T, Glenthoj BY. Acute effects of antipsychotics and diazepam on prepulse inhibition of the startle response. Schizophrenia Research 2003; Vol. 60, issue 1 Suppl 1:100.
Lamure 2003 {published data only}
    1. Lamure M, Toumi M, Chabannes J‐P, Dansette G‐Y, Benyaya J, Hansen K. Zuclopenthixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis. International Journal of Psychiatry in Clinical Practice 2003;7(3):177‐85.
Lemmens 1994 {published data only}
    1. Lemmens P, Smedt G, Gheuens J, Tritsmans L. Efficacy of risperidone in the treatment of schizophrenia. Proceedings of the 7th Biennial Winter Workshop on Schizophrenia; 1994 Jan 23‐28; Les Diablerets, Switzerland 1994; Vol. 11, issue 2:106.
Liu 1997b {published data only}
    1. Liu P, Bian H, Chen H. Observation of clinical effect of clopixol‐acuphase injection for acute psychosis. Chinese Journal of Pharmaco Epidemiology [药物流行病学杂志] 1997; Vol. 6, issue 4:202‐4.
Liu 1998a {published data only}
    1. Liu S. A follow‐up of effects of sustain treatment of clopixol and cpz in schizophrenic patients. Sichuan Mental Health [四川精神卫生] 1998; Vol. 11, issue 3:162‐3.
Loza 2001 {published data only}
    1. Loza B, Kucharska‐Pietura K, Debowska G. Atypical versus typical antipsychotic treatment prognosis in first‐episode paranoid schizophrenia based on wcst and dichotic listening scores. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey) 2001;11(3):285. [14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2103#]
Lublin 1991 {published data only}
    1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology 1991;1(4):541‐8. [EMBASE 1998035700] - PubMed
Mackeprang 2001 {published data only}
    1. Mackeprang T, Fagerlund B, Videbaek C, Hemmingsen RP, Glenthoj BY. Extrastriatal dopamine(d2/d3)‐receptor occupancy and cognition in first episode schizophrenic patients. Schizophrenia Research 2001;49(Suppl.1,2):194. [LMD163341]
Malt 1995 {published data only}
    1. Malt UF, Nystad R, Bache T, Noren O, Sjaastad M, Solberg KO, et al. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients. British Journal of Psychiatry 1995;166(3):374‐7. [MEDLINE: ; PMID 7788130] - PubMed
Mann 1985 {published data only}
    1. Mann BS, Moslehuddin KS, Owen RT, Clayton AR, Rohatgi KK, Sud P, et al. A clinical assessment of zuclopenthixol dihydrochloride ('Clopixol Tablets') in the treatment of psychotic illness. Pharmatherapeutica 1985;4(6):386392. - PubMed
Martyns 1993 {published data only}
    1. Martyns Yellowe IS. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in‐patients. Implications for community psychiatry. West African Journal of Medicine 1993;12(2):110‐3. [MEDLINE: ; PMID 8104468] - PubMed
    1. Martyns‐Yellowe IS. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West African Journal of Medicine 1994;13(4):200‐3. [MEDLINE: ; PMID 7756183] - PubMed
Mazurek 2003 {published data only}
    1. Mazurek I, Loza B, Lecyk A. Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia. Journal of the European College of Neuropsychopharmacology 2003;13(4):S347. [P.2.156]
Meyers 1972 {published data only}
    1. Meyers C, Lhoas JP, Huvelle R. Rediscovery of a neuroleptic drug in a new form: clopenthixol [Redecouverte d'un neuroleptique sous une autre presentation: le clopenthixol]. Schweizerische Rundschau fur Medizin Praxis 1972;61(26):869‐71. [Cochrane Library CN‐00282616] - PubMed
Mosolov 2000 {published data only}
    1. Mosolov SN, Molodetskikh AV, Eryomin AV, Graikov GM, Nourislamov SV. Effect and tolerability of Clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomized investigation. Sotsial'Naia I KlinIcheskaia Psikhiatria 2000;10(2):47‐52. [MEDLINE: ; PMID 4967871] - PubMed
NCT00206960 {published data only}
    1. NCT00206960. Effects of classical and atypical antipsychotics on dopamine receptor binding of 123i‐epidepride, cognition, startle response and extrapyramidal side‐effects in drug‐naive first‐episode schizophrenic patients. http://www.clinicaltrials.gov 2005.
Pagsberg 2004 {published data only}
    1. Pagsberg A, Jagersma E, Baare W, Mackeprang T, Glenthoej by. Change in caudate nucleus volume after three‐month treatment in drug‐ naive first‐episode schizophrenia patients. Schizophrenia Research 2004;67(1):99.
Ropert 1988 {published data only}
    1. Ropert R, Hoepfner Petersen HE, Benyay J. Where zuclopenthixol acetate stands amid the 'modified release' neuroleptics [Place de l'acetate de zuclopenthixol au sein des neuroleptiques a liberation modifiee]. Congres de Psychiatrie et de Neurologie de Langue Francaise, LXXXVIth Session; 1988 Jun 13‐17; Chambery, France. 1988:350‐62. [MEDLINE: ; PMID 3615572] - PubMed
Rubio 2005 {published data only}
    1. Rubio G, Martínez‐Gras I, Ponce G, López‐Muñoz F, Alamo C, Jimenez‐Arriero MA, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long‐term controlled study. European Neuropsychopharmacology 2005;15(Suppl 3):S476.
Rubio 2006 {published data only}
    1. Rubio G, Martinez I, Ponce G, Jimenez‐Arriero MA, Lopez‐Munoz F, Alamo C. Long‐acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]. Canada, 2006; Vol. 51, issue 8:531‐9. [MEDLINE: ] - PubMed
    1. Rubio G, Martinez‐Gras I, Ponce G, Jiménez‐Arriero MA, López‐Muñoz F, Alamo C. Long‐acting injectable risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada 2006.
Rubio 2009 {published data only}
    1. Rubio G, Rodriguez‐Jimenez R, Martinez‐Gras I, Jimenez‐Arriero MA, Palomo T. Prepulse inhibition of the startle response in amisulpride‐treated patients: comparison with typical antipsychotics. Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28‐Jul 2 ;Paris, France. 2009:394.
Rubioz 2006 {published data only}
    1. Rubioz G, Martine I, Recio A, Ponce G, Lopez‐Munoz F, Alamo C, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long‐term randomized, controlled, crossover study. European Journal of Psychiatry 2006;20(3):133‐46.
Saxena 1990b {published data only}
    1. Saxena B, MacCrimmon D, Busse E, Turner P, Cooper L, Kenny J, et al. I.M clopixol v/s modecate in chronic schizophrenia – a double‐blind study. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan 1990:247.
Saxena 1996 {published data only}
    1. Saxena B. The value of depot neuroleptic injections in the treatment of chronic schizophrenia. Schizophrenia 1996 ‐ Breaking down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6‐9; Vancouver, Canada. 1996. [MEDLINE: ; PsycINFO 1973‐29665‐001; PMID 4715636] - PubMed
Schooler 1993 {published data only}
    1. Schooler NR, Keith SJ, Severe JB, Matthews SM. Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome. International Congress on Schizophrenia Research 1993;9:260.
Shelton 1969 {published data only}
    1. Shelton WH, Bishop MP, Gallant DM. The Achilles reflex and antipsychotic drugs. Current Therapeutic Research Clinical and Experimental 1969;11(1):22‐6. [MEDLINE: ; PMID 4973850] - PubMed
Singh 1992 {published data only}
    1. Singh I, Owino WJE. A double‐blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in‐patients with associated behavioural disorders. Journal of Intellectual Disability Research 1992;36:541‐9. - PubMed
Sofronov 2013 {published data only}
    1. Sofronov A, Spikina A, Savelyev A. The role of modern antipsychotics in correction of neurocognitive deficit in schizophrenia patients. European Psychiatry 2013; Vol. 28:1247.
Svestka 1986 {published data only}
    1. Svestka J, Nahunek K, Ceskova E. Controlled cross‐over comparison of oxyprothepine and clopenthixol decanoate in the prophylaxis of schizophrenic psychoses. Activitas Nervosa Superior 1986;28(1):35‐6. [PsycINFO 75‐08452]
Syvalahti 1997 {published data only}
    1. Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, ET AL. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24‐32. [MEDLINE: ; PMID 9027670] - PubMed
Taymeeyapradit 2002 {published data only}
    1. Taymeeyapradit U, Kuasirikul S. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. Journal of the Medical Association of Thailand 2002;85(12):1301‐8. [MEDLINE: ] - PubMed
Tegeler 1985 {published data only}
    1. Tegeler J. A comparative trial of Cis(Z)‐clopenthixol‐decanoate and fluphenazine‐decanoate. Pharmacopsychiatry 1985;18(1):78‐9. [MEDLINE: ; PMID 9027670] - PubMed
Uys 1996 {published data only}
    1. Uys H, Berk M. A controlled double blind study of zuclopenthixol acetate compared to clothiapine in acute psychosis including mania and exacerbation of chronic psychosis. Unpublished Report 1996. [MEDLINE: ]
    1. Uys H, Berk M. A controlled double blind study of zuclopenthixol acetate compared with clothiapine in acute psychosis including mania and exacerbation of chronic psychosis. 20th Congress of the Collegium Internationale Neuro‐psychopharmacologicum; 1996 Jun 23‐27; Melbourne, Australia. 1996. [MEDLINE: ; PsycINFO 52‐05954; PMID 4589640] - PubMed
Venkateswarlu 1990 {published data only}
    1. Venkateswarlu T, Staley CJ, Neal CD. Zuclopenthixol dihydrochloride in the management of behavioural disorders in elderly demented patients:a dose‐ranging study. International Journal of Geriatric Psychiatry 1990;5(4):265‐70.
Viala 1988 {published data only}
    1. Viala A, Ba B, Durand A, Gouezo F, Hou N, Jorgensen A. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology 1988;94(3):293‐7. [MEDLINE: ; PMID 2895936] - PubMed
Walker 1983 {published data only}
    1. Walker CA. A double‐blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out‐ patients. Pharmatherapeutica 1983;3(5):289‐93. [MEDLINE: ; PMID 6133287] - PubMed
Weiser 1975 {published data only}
    1. Weiser G, Tahedl A, Reisecker F, Meyer H. Advantages of the initial therapy of acute schizophrenia with large doses of droperidol/A comparative study (author's transl) [Vorteile der Initialbehandlung akuter Schizophrenien mit hochdosiertem Droperidol. Eine Vergleichsstudie]. Arzneimittel Forschung 1975;25(11):1845‐8. [MEDLINE: ; PMID 1243093] - PubMed
Wisted 1990 {published data only}
    1. Wistedt B, Koskinen T, Thelander S, Pedersen V, Molberg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia ‐ a double‐blind, multicenter study. Psychopharmacology 1990; Vol. 100, issue 4:23. - PubMed
Wistedt 1991 {published data only}
    1. Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Molbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double‐blind multicentre study. Acta Psychiatrica Scandinavica 1991;84(1):14‐21. [MEDLINE: ; PMID 1681680] - PubMed
Xiaanao 1999 {published data only}
    1. Xiaanoao G, Jiaju X, Mingshen W. Efficacy of clopenthixol in treating delusions and halucinations in schizophrenia. Journal of Clinical Psychology 1999;9(4):202‐3.
Youssef 1991 {published data only}
    1. Youssef HA. Duration of neuroleptic treatment and relapse rate: a 5‐year follow‐up study with haloperidol decanoate. Clinical Neuropharmacology 1991;14(suppl.2):S16‐S23. - PubMed

Additional references

Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. - PMC - PubMed
Awad 1997
    1. Awad GA, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997;11(1):32‐47. - PubMed
Bland 1997
    1. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106] - PubMed
Chouinard 1980
    1. Chouinard G, Ross‐Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Science 1980;7:233.
da Silva Freire Coutinho 1999
    1. Silva Freire Coutinho E, Fenton M, Quraishi SN. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001164] - DOI - PMC - PubMed
Dally 1967
    1. Dally P. Chemotherapy of Psychiatric Disorders. London: Logos Press Limited, 1967.
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9. - PubMed
Dollery 1999
    1. Dollery. Drug discovery and development in the molecular era. British Journal of Clinical Pharmacology January 1999;47(1):5‐6. - PMC - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80. - PubMed
Egger 1997
    1. Egger M, Zellweger‐Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326‐9. - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10. - PubMed
Gulliford 1999
    1. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83. - PubMed
Guy 1976
    1. Guy U. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hutton 2009
    1. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30. - PubMed
Jablensky 1992
    1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten‐country study. Psychological Medicine 1992;20(Monograph Supplement):1‐97. - PubMed
Jayakody 2012
    1. Jayakody K, Gibson RC, Kumar A, Gunadasa S. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD000525.pub3] - DOI - PMC - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Kay 1987
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261‐76. - PubMed
Kozyrev 2003
    1. Kozyrev VN, Smulevich AB, Drobizhev MIu, Kraeva GK, Kubrakov MA. Psychotropic drugs used in a psychiatric hospital (pharmaco‐epidemiologic aspects).. Zhurnal Nevrologii Psikhiatrii Im S S Korsakova 2003;103(11):25‐32. - PubMed
Leon 2006
    1. Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632] - PubMed
Leucht 2005
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797] - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856] - PubMed
Lingjaerde 1987
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatrica Scandinavica Supplementum 1987;76(334):100. - PubMed
Mace 2005
    1. Mace S, Taylor D. A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance. International Journal of Psychiatry in Clinical Practice 2005;9(2):124‐9. - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales ‐ a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Moher 2001
    1. Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet 2001;357:1191‐4. - PubMed
Montgomery 1979
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382‐9. - PubMed
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Percudani 2005
    1. Percudani M. Barbui C. Fortino I. Petrovich L. Epidemiology of first‐ and second‐generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry 2005;38(3):128‐31. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Taylor 2000
    1. Taylor D, Kerwin R. Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol. Psychiatric Bulletin 2000;24:106‐8.
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii‐92. [MEDLINE: ] - PubMed
WHO 2010
    1. Multiple. Pocket Guide to the ICD‐10 Classification of Mental and Behavioural Disorders. 16. Elsevier, 2010.
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.

References to other published versions of this review

Kumar 2005
    1. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005474] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources